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Bilateral adrenal pheochromocytoma with a germline 
L790F mutation in the RET oncogene
Jun Won Min, Youn Joon Park, Hee Jin Kim
1, Myung-Chul Chang
Departments of Surgery and 
1Internal Medicine, Dankook University College of Medicine, Cheonan, Korea
About ten percent of pheochromocytomas are associated with familial syndrome. Hereditary pheochromocytoma has char-
acteristics of early onset, multifocality and bilaterality. We experienced a case of 44-year-old man with bilateral pheochromo-
cytoma without evidence of medullary thyroid cancer. Genetic test detected a L790F germline mutation of RET oncogene. 
The author found a necessity for genetic tests in cases of young-age, bilateral pheochromocytoma.
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INTRODUCTION
Pheochromocytoma was well known as “10 percent tu-
mor”. It is widely believed that approximately 10% of 
pheochromocytomas are associated with familial syn-
dromes. However, it is now recognized that the frequency 
of germline mutations in apparently sporadic pheochro-
mocytoma is as high as 24% [1]. Hereditary pheochromo-
cytoma could be a phenotype of multiple endocrine neo-
plasia (MEN) type 2, Von Hipple-Lindau disease, familial 
pheochromocytoma-paraganglioma and neurofibroma-
tosis type 1. The causal genes were discovered as RET, 
VHL, SDHB, SDHD and NF1 respectively. Each genetic 
syndromes share common characteristics such as early on-
set, multifocality and bilaterality. So in case of young- 
aged, bilateral pheochromocytoma, searching for genetic 
m u t a t i o n  i s  r e c o m m e n d e d  [ 2 ] .  W e  r e p o r t  a  c a s e  o f  a  
44-year-old man with bilateral pheochromocytomas 
whose genetic study shows a rare germline L790F muta-
tion of RET oncogene.
CASE REPORT
A 44-year-old man was admitted for incidentally found 
bilateral bulky adrenal mass lesions. He daily drank one or 
two bottles of Soju (Korean distilled spirits). A computed 
tomography (CT) scan was taken for evaluation of alco-
holic liver disease. He felt paroxysmal attack of palpitation 
and sweating since last year, but had no medication. His 
systolic blood pressure was 110 mmHg and diastolic 
blood pressure was 65 mmHg. His heart rate was 70 per 
minute. On the physical examination, no mass was pal-
pable in abdomen and neck lesion. Jun Won Min, et al.
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Fig. 1. Abdominal computed tomography scan shows huge mass in 
both adrenal glands.
Fig. 2. Single photon emission computed tomography image of 
I-123 metaiodobenzylguanidine scan shows bilateral adrenal 
uptake.
Fig. 3. (A) Cut surface of 
right adrenal gland 
shows well‐demarcated,
multilocular cystic mass. 
It contains bloody, dark 
red brown coloredfluid. 
(B) Cut surface of left 
adrenal gland shows 
soft, variegated, red-
dish pink mass with a 
few small cysts.
Fig. 4. Genetic testing detected mutation in codon 790 (L790F) of 
RET oncogene.
  In the hormonal studies, 24 hours urinary meta-
nephrine and vanillylmandelic acid was elevated as 6.12 
mg/day (normal value, less than 1.3 mg/day) and 23.38 
mg/day (normal value, less than 8 mg/day). Twenty-four 
hours urinary cortisol was normal as 45.9 ug/day (normal 
value, 20 to 90 ug/day). Plasma rennin activity and aldos-
terone level was also normal as 0.44 ng/mL/hr (normal val-
ue, 0.15 to 2.33 ng/mL/hr) and 65.0 pg/mL (normal value, 
35.7 to 240.0 pg/mL).
On the CT scan, right adrenal mass was 6 cm sized, well 
defined and mostly necrotic. The left adrenal mass was 8 
cm, hypervascular and centrally necrotic (Fig. 1). I-123 
metaiodobenzylguanidine scan showed bilateral adrenal 
uptake with no evidence of metastasis (Fig. 2).
The patient was diagnosed as bilateral pheochromo-
cytomas. After prescribing alpha-blocker terazosin for 
twelve days, bilateral adrenalectomy was done under gen-
eral anesthesia. On the operation, both adrenal masses Pheochromocytoma with L790F mutation
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Fig. 5. Family pedigree shows no evidence of medullary thyroid 
cancer or endocrine disease. All of his family members are alive. 
Arrow indicates index patient.
were well marginated without invasion and lymph node 
metastasis (Fig. 3). The pathological diagnosis was also 
pheochromocytoma. He was recovered uneventfully, dis-
charged with gluco-corticoid and mineralo-corticoid 
replacement.
We tested germline mutation of RET oncogene with pa-
tient’s informed consent. Germline mutation was ana-
lyzed by direct sequencing of exons 10, 11, 13, 14, 15, 16 of 
RET oncogene. At the codon 790 of exon 13, missense mu-
tation of L790F was found. It was a point mutation of DNA 
change from TTG to TTT, resulted amino acid change from 
Leucine to Phenylalanine (Fig. 4). 
After the result of germline mutation of RET oncogene, 
we diagnosed the patient as multiple endocrine neoplasia 
type 2A, and searched an evidence of medullary thyroid 
cancer in the patient and his family members. In his family 
members, there was no history of thyroid cancer or endo-
crine diseases (Fig. 5). We checked an ultrasonography of 
patient’s thyroid, but there was no evidence of thyroid 
nodule. The patient’s calcitonin level was 3.7 pg/mL 
(normal value, less than 20 pg/mL). We checked the stimu-
lated calcitonin level, but the result was also normal range. 
We explained the results and recommended prophylactic 
total thyroidectomy and genetic test about his parents, but 
he rejected. So we made a plan to check the calcitonin and 
thyroid ultrasonography regularly. 
DISCUSSION
About 10 percent of pheochromocytomas were as-
sumed to be hereditary. However, recent advances of ge-
netic studies show much higher germline mutation rates 
than that of previous reports. According to the European 
Network for the Study of Adrenal Tumors Pheochromocy-
toma Working Group [2], germline mutation rate was 
25.9% from 642 pheochromocytoma and paraganglioma 
patients. In the other study [1], 24.3% of the 271 sporadic 
pheochromocytoma patients had germline mutations. It is 
now estimated that about 20 to 30% of pheochromocyto-
mas have hereditary tendency.
Hereditary pheochromocytoma is a phenotype of five 
genes; VHL, RET, SDHB, SDHD and NF1. From the reports 
of the European Network [2], each mutation rates were 
8.7% in VHL gene, 5.3% in SDHB, 4.8% in SDHD, 4.8% in 
RET and 3.7% in NF1 respectively. Other European study 
[1] shows similar results; 11.1% in VHL, 4.4% in SDHB, 
4.1% in SDHD, 4.8% in RET.  
Each genetic syndrome has characteristic phenotypes. It 
is possible to anticipate genotype by characteristic pheno-
type, so identification of clinical characteristics is very 
important. Genetic testing for NF1 gene is not routinely 
carried out. Diagnosis of neurofibromatosis type 1 is pos-
sible based on the typical clinical features; café-au-lait 
spots, neurofibromas and axillary and inguinal freckling. 
On the contrary, genetic test of NF1 gene is difficult and 
costly due to large sized NF1 gene, composed of 57 exons 
without hot spots. In this case we can exclude NF1 muta-
tion based on the clinical features.
Von Hippel-Lindau disease is characterized by he-
mangioblastomas, renal tumors, pancreatic and endolym-
phatic sac tumors. Pheochromocytomas occur in about 
26% of von Hippel-Lindau patients [3]. Associated pheo-
chromocytoma is typically lack of phenylethanolamine- 
N-methyltransferase which converts noradrenaline to 
adrenaline, resulted in high normetanephrine and normal 
metanephrine [4]. In this case, we can rule out VHL muta-
tion due to high level of metanephrine.  
SDHB and SDHD gene are recently identified as para-
ganglioma syndrome type 4 and type 1. These genes are 
subunits of the mitochondrial complex II, which is in-Jun Won Min, et al.
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volved in the Krebs cycle as succinate dehydrogenase. 
Pheochromocytoma with SDHB and SDHD germline mu-
tation is frequently malignant, extra-adrenal or bilateral. 
So in that phenotype, genetic test about SDHB and SDHD 
gene are necessary [2].
Germline mutation of RET oncogene is associated with 
MEN type 2 which has typical character of genotype-phe-
notype correlation and mutation hot spots. Medullary 
thyroid cancer is the most frequent and malignant tumor 
in MEN type 2. MEN type 2 was classified according to the 
aggressiveness and onset of medullary thyroid cancer. The 
penetrance of medullary thyroid cancer is different ac-
cording to the mutation site. Patients with level 1 muta-
tions (codons 609, 768, 790, 791, 804 and 891) have the low-
est risk for medullary thyroid cancer, patients with level 2 
mutations (codons 611, 618, 620 and 634) are intermediate 
risk, and patient with level 3 mutations (codons 883 and 
918) have the highest risk for medullary thyroid cancer [5]. 
Medullary thyroid cancer was developed in 100% of level 
3, 73% of level 2 and only 45% of level 1 RET gene mutation 
[6].
In this case, L790F mutation was found in RET onco-
gene, which was not reported before in Korea. 1998, 
Berndt et al. [7] first described a new hot spot for muta-
tions affecting codon 790 of RET oncogene. They reported 
that nine (69%) of 13 carriers with L790F mutation had de-
veloped medullary thyroid cancer. Initially, L790F muta-
tion was reported to be associated with pheochromocyto-
ma, but in the following study [8], L790F mutation rarely 
associated with pheochromocytoma. 
Interestingly, this case shows bilateral pheochromocy-
tomas which was rare phenotype of L790F and does not 
show medullary thyroid cancer which was common phe-
notype of L790F. Machens et al. [6] reported that mean di-
agnostic age of pheochromocytoma was 46.5 years and 
medullary thyroid cancer was 51.6 years in level 1 RET 
mutation. We can expect patient’s occurrence of medullary 
thyroid cancer in the near future. 
Like as risk classification of medullary thyroid cancer, 
risk of pheochromocytoma also can be classified. The 
highest-risk category of pheochromocytoma includes 
SDHB, SDHD and the level 3 risk of RET; the high-risk cat-
egory includes VHL missense mutation and the level 2 risk 
of RET; the least-high risk category includes VHL truncat-
ing mutations and level 1 risk of RET [9]. 
The incidence of germline mutation of multifocal or bi-
lateral pheochromocytomas was much higher than that of 
unilateral pheochromocytoma. In the 26 patients of multi-
focal or bilateral pheochromocytomas, 80% of them had a 
mutation (46% in VHL, 19% in RET, 15% in SDHD, none in 
SDHB). In the other study [10], 12 RET, 1 VHL, 1 SDHD 
gene mutations were found in the 23 bilateral pheochro-
mocytomas. They recommended sequential mutational 
analysis of RET, followed by VHL and SDHD in bilateral 
pheochromocytoma. 
This case is the first report of L790F RET germline muta-
tion in Korea. In case of bilateral pheochromocytoma, 
germline mutation test for hereditary pheochromocytoma 
is necessary. 
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